Difference between revisions of "Belinostat (Beleodaq)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Chemotherapy" to "Category:Chemotherapeutic") |
m |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Histone deacetylase (HDAC) inhibitor. Belinostat causes cell cycle arrest and/or apoptosis of tumor cells by blocking HDAC, which results in accumulation of acetylated histones and other proteins.<ref name=insert>[http://beleodaq.com/ Belinostat (Beleodaq) package insert]</ref><ref>[[Media:Belinostat.pdf | Belinostat (Beleodaq) package insert (locally hosted backup)]]</ref><ref>[http://beleodaq.com/ Beleodaq manufacturer's website]</ref> | + | Class/mechanism: Histone deacetylase (HDAC) inhibitor. Belinostat causes cell cycle arrest and/or apoptosis of tumor cells by blocking HDAC, which results in accumulation of acetylated histones and other proteins.<ref name=insert>[http://beleodaq.com/downloads/Beleodaq_PI.pdf Belinostat (Beleodaq) package insert]</ref><ref>[[Media:Belinostat.pdf | Belinostat (Beleodaq) package insert (locally hosted backup)]]</ref><ref>[http://beleodaq.com/ Beleodaq manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| Line 11: | Line 11: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *Patient information may be found in the [http://beleodaq.com/ Belinostat (Beleodaq) package insert].<ref name=insert></ref> | + | *Patient information may be found in the [http://beleodaq.com/downloads/Beleodaq_PI.pdf Belinostat (Beleodaq) package insert].<ref name=insert></ref> |
*[http://www.chemocare.com/chemotherapy/drug-info/belinostat.aspx Belinostat (Beleodaq) patient drug information (Chemocare)]<ref>[http://www.chemocare.com/chemotherapy/drug-info/belinostat.aspx Belinostat (Beleodaq) patient drug information (Chemocare)]</ref> | *[http://www.chemocare.com/chemotherapy/drug-info/belinostat.aspx Belinostat (Beleodaq) patient drug information (Chemocare)]<ref>[http://www.chemocare.com/chemotherapy/drug-info/belinostat.aspx Belinostat (Beleodaq) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/belinostat-patient-drug-information Belinostat (Beleodaq) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/belinostat-patient-drug-information Belinostat (Beleodaq) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/belinostat-patient-drug-information Belinostat (Beleodaq) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/belinostat-patient-drug-information Belinostat (Beleodaq) patient drug information (UpToDate)]</ref> | ||
Revision as of 15:00, 10 September 2019
General information
Class/mechanism: Histone deacetylase (HDAC) inhibitor. Belinostat causes cell cycle arrest and/or apoptosis of tumor cells by blocking HDAC, which results in accumulation of acetylated histones and other proteins.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Patient information may be found in the Belinostat (Beleodaq) package insert.[1]
- Belinostat (Beleodaq) patient drug information (Chemocare)[4]
- Belinostat (Beleodaq) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 7/3/2014: FDA accelerated approval "for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)."
Also known as
- Code name: PXD101
- Brand name: Beleodaq